The search result changed since you submitted your search request. Documents might be displayed in a different sort order.
  • search hit 1 of 335
Back to Result List

Personalized antibiotic therapy for the critically ill: Implementation strategies and effects on clinical outcome of piperacillin therapeutic drug monitoring — a descriptive retrospective analysis

Please always quote using this URN: urn:nbn:de:bvb:20-opus-250052
  • Therapeutic drug monitoring (TDM) is increasingly relevant for an individualized antibiotic therapy and subsequently a necessary tool to reduce multidrug-resistant pathogens, especially in light of diminishing antimicrobial capabilities. Critical illness is associated with profound pharmacokinetic and pharmacodynamic alterations, which challenge dose finding and the application of particularly hydrophilic drugs such as β-lactam antibiotics. Methods: Implementation strategy, potential benefit, and practicability of the developed standardTherapeutic drug monitoring (TDM) is increasingly relevant for an individualized antibiotic therapy and subsequently a necessary tool to reduce multidrug-resistant pathogens, especially in light of diminishing antimicrobial capabilities. Critical illness is associated with profound pharmacokinetic and pharmacodynamic alterations, which challenge dose finding and the application of particularly hydrophilic drugs such as β-lactam antibiotics. Methods: Implementation strategy, potential benefit, and practicability of the developed standard operating procedures were retrospectively analyzed from January to December 2020. Furthermore, the efficacy of the proposed dosing target of piperacillin in critically ill patients was evaluated. Results: In total, 160 patients received piperacillin/tazobactam therapy and were subsequently included in the study. Of them, 114 patients received piperacillin/tazobactam by continuous infusion and had at least one measurement of piperacillin serum level according to the standard operating procedure. In total, 271 measurements were performed with an average level of 79.0 ± 46.0 mg/L. Seventy-one piperacillin levels exceeded 100 mg/L and six levels were lower than 22.5 mg/L. The high-level and the low-level group differed significantly in infection laboratory parameters (CRP (mg/dL) 20.18 ± 11.71 vs. 5.75 ± 5.33) and renal function [glomerular filtration rate (mL/min/1.75 m2) 40.85 ± 26.74 vs. 120.50 ± 70.48]. Conclusions: Piperacillin levels are unpredictable in critically ill patients. TDM during piperacillin/tazobactam therapy is highly recommended for all patients. Although our implementation strategy was effective, further strategies implemented into the daily clinical workflow might support the health care staff and increase the clinicians' alertness.show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: Nikolas Schrader, Thorsten Riese, Max Kurlbaum, Patrick MeybohmORCiD, Markus Kredel, Güzin Surat, Oliver Scherf-Clavel, Alexander Strate, Andreas Pospiech, Kerstin Hoppe
URN:urn:nbn:de:bvb:20-opus-250052
Document Type:Journal article
Faculties:Medizinische Fakultät / Klinik und Poliklinik für Anästhesiologie (ab 2004)
Medizinische Fakultät / Medizinische Klinik und Poliklinik I
Fakultät für Chemie und Pharmazie / Institut für Pharmazie und Lebensmittelchemie
Language:English
Parent Title (English):Antibiotics
ISSN:2079-6382
Year of Completion:2021
Volume:10
Issue:12
Article Number:1452
Source:Antibiotics (2021) 10:12, 1452. https://doi.org/10.3390/antibiotics10121452
DOI:https://doi.org/10.3390/antibiotics10121452
Sonstige beteiligte Institutionen:Krankenhaushygiene und Antimicrobial Stewardship, Universitätsklinikum Würzburg
Sonstige beteiligte Institutionen:Zentrallabor, Universitätsklinikum Würzburg
Sonstige beteiligte Institutionen:Apotheke, Universitätsklinikum Würzburg
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Tag:antimicrobial stewardship; personalized antimicrobial therapy; piperacillin/tazobactam; therapeutic drug monitoring
Release Date:2023/02/06
Date of first Publication:2021/11/26
Licence (German):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International